Biocon & Tabuk Partner for Diabetes Treatment in Middle East
By Rediff Money Desk, MUMBAI Sep 26, 2024 17:29
Biocon inks licensing and supply agreement with Tabuk Pharmaceuticals for commercializing its 'GLP-1' products for diabetes and weight management in the Middle East.
New Delhi, Sep 26 (PTI) Biocon Ltd on Thursday said it has signed a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company to commercialise its 'GLP-1' products for treating diabetes and chronic weight management in select countries of the Middle East.
Under the agreement, the company will develop and manufacture the products and Tabuk Pharmaceuticals -- a fully-owned subsidiary of Astra Industrial Group, a leading pharmaceutical company in the Middle East and North Africa (MENA) region, will hold the marketing authorisation rights, and be responsible to register, import and promote them in the region, Biocon said in a regulatory filing.
The agreement also provides for a provision to expand to other 'GLP' products, as well as the option of a tech transfer that will enable localised manufacturing at a later stage, it added.
The partnership with Tabuk Pharmaceuticals paves the way for the company's vertically integrated, complex GLP1 formulations entry into Saudi Arabia and other countries in the region, Biocon CEO and Managing Director Siddharth Mittal said.
"The partnership is further validation of our concerted focus on GLPs and Peptides as future growth drivers," he added.
Tabuk Pharmaceuticals CEO Ismail Shehadah said the partnership with Biocon will enable the company to deliver unique health solutions aimed at enhancing the well-being of people in Saudi Arabia and other countries it operates in.
"We are confident that this partnership supports our efforts to manufacture and localise a range of GLP-1 products in the region and strengthen our market leading position in the area of diabetes medications, in line with our strategy," Shehadah added.
Under the agreement, the company will develop and manufacture the products and Tabuk Pharmaceuticals -- a fully-owned subsidiary of Astra Industrial Group, a leading pharmaceutical company in the Middle East and North Africa (MENA) region, will hold the marketing authorisation rights, and be responsible to register, import and promote them in the region, Biocon said in a regulatory filing.
The agreement also provides for a provision to expand to other 'GLP' products, as well as the option of a tech transfer that will enable localised manufacturing at a later stage, it added.
The partnership with Tabuk Pharmaceuticals paves the way for the company's vertically integrated, complex GLP1 formulations entry into Saudi Arabia and other countries in the region, Biocon CEO and Managing Director Siddharth Mittal said.
"The partnership is further validation of our concerted focus on GLPs and Peptides as future growth drivers," he added.
Tabuk Pharmaceuticals CEO Ismail Shehadah said the partnership with Biocon will enable the company to deliver unique health solutions aimed at enhancing the well-being of people in Saudi Arabia and other countries it operates in.
"We are confident that this partnership supports our efforts to manufacture and localise a range of GLP-1 products in the region and strengthen our market leading position in the area of diabetes medications, in line with our strategy," Shehadah added.
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Srestha Finvest
- 0.66 (+ 4.76)
- 32896927
- Vodafone Idea L
- 8.45 (+ 4.06)
- 28557277
- Standard Capital
- 1.14 (+ 0.88)
- 17361276
- Alstone Textiles
- 0.83 (+ 5.06)
- 14796552
- AvanceTechnologies
- 0.89 (+ 4.71)
- 10049569
MORE NEWS
Coal India Aims for Dividend Return by FY'26
Coal India aims to eliminate ECL's losses and rejoin the dividend list by FY'26, with...
Gold Poised for 15-18% Returns in Samvat 2081:...
Analysts predict a strong 15-18% return for gold in Samvat 2081, driven by positive...
Punjab Paddy Procurement Crosses 85 Lakh...
Punjab has procured 85.41 lakh tonnes of paddy in the 2024-25 kharif marketing season,...